Company / Cash & Equivalents
Zenas BioPharma, Inc. Cash & Equivalents History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$110.6M
FY2025
5-year range
$56.9M / $319.7M
FY2023-FY2025
Trend
-65.4%
vs FY2024
Sector context
#137 of 207
Health Care
What the data says
At $111M, Zenas BioPharma, Inc.'s cash & equivalents ranks #137 of 207 in the Health Care sector. Improved from $57M to $111M over the past 2 years.
Based on SEC 10-K filings.
$111M in FY2025.
Improved from $57M to $111M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#137 of 207 in Health CareTop 66% of 207This company $110.6M Sector average $669.5M
▼
-83.5% below sector average
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 65.4% year-over-year.
- Ranks #137 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $110.6M | -65.4% |
| FY2024 | $319.7M | +462.4% |
| FY2023 | $56.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026